Citovirax (Ganciclovir)

Citovirax is indicated for the treatment and prevention of cytomegalovirus (CMV) infections in specific patient populations.

• Treatment of systemic CMV disease such as CMV pneumonia, colitis, or hepatitis.
• Management of CMV retinitis in immunocompromised individuals, particularly those with AIDS or organ transplants.
• Prophylactic therapy to prevent CMV infection in solid‑organ or hematopoietic stem‑cell transplant recipients.
• Treatment of CMV infection in patients with weakened immune systems due to chemotherapy or other immunosuppressive conditions.
• Use as part of combination therapy when monotherapy is insufficient for severe CMV disease.

Adverse reactions to Citovirax may vary in frequency and severity; they are typically reported during or after intravenous administration.

Common

• Injection‑site pain, erythema, or phlebitis.
• Mild fever, chills, or headache.
• Transient elevations in liver enzymes (ALT, AST).
• Nausea or vomiting.
• Diarrhea.

Serious

• Neutropenia or other significant bone‑marrow suppression.
• Acute kidney injury or worsening renal function.
• Severe hypersensitivity reactions, including rash, angioedema, or anaphylaxis.
• Seizures or neurotoxicity.
• Thrombocytopenia.
• Significant drug‑resistant CMV infection.

Before initiating Citovirax therapy, clinicians should evaluate patient-specific factors and monitor for potential complications associated with antiviral treatment.

• Assess renal function; dose adjustment may be required in patients with impaired clearance.
• Perform baseline complete blood count (CBC) and monitor for neutropenia or thrombocytopenia during therapy.
• Monitor liver function tests regularly, especially in patients with pre‑existing hepatic disease.
• Use caution in pregnant or breastfeeding women, as safety data are limited.
• Avoid concurrent use with other nephrotoxic or myelosuppressive agents when possible.
• Evaluate for potential drug‑resistant CMV strains in patients with prior antiviral exposure.

Citovirax can interact with other medicines, influencing its efficacy or increasing toxicity; awareness of these interactions supports safe use.

Avoid

• Concomitant use with other strong nephrotoxic agents (e.g., aminoglycosides, amphotericin B) should be avoided due to additive renal toxicity.
• Co‑administration with myelosuppressive chemotherapy agents should be avoided because of heightened risk of bone‑marrow suppression.

Use with caution

• Use with caution when combined with other antiviral agents such as foscarnet, as additive hematologic toxicity may occur.
• Caution is advised when prescribing with drugs that are highly protein‑bound, which may alter ganciclovir plasma levels.
• Adjust dosage when used with medications that affect renal tubular secretion (e.g., probenecid).